Kenvue (KVUE) to Release Quarterly Earnings on Thursday

Kenvue (NYSE:KVUE) will likely be posting its quarterly earnings results before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of $0.26 per share and revenue of $3.79 billion for the quarter. Kenvue has set its FY 2024 guidance at 1.100-1.200 EPS and its FY24 guidance at $1.10-1.20 EPS.Parties that are interested in participating in the company’s conference call can do so using this link.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.27 by $0.01. The business had revenue of $3.90 billion during the quarter, compared to the consensus estimate of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. Kenvue’s revenue was down .4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.31 EPS. On average, analysts expect Kenvue to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Kenvue Stock Down 2.0 %

Kenvue stock opened at $20.81 on Wednesday. Kenvue has a twelve month low of $17.67 and a twelve month high of $24.46. The stock has a market cap of $39.89 billion, a P/E ratio of 37.83, a P/E/G ratio of 2.05 and a beta of 1.45. The company’s 50-day moving average price is $21.77 and its two-hundred day moving average price is $21.96. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be paid a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.94%. Kenvue’s dividend payout ratio (DPR) is currently 149.09%.

Analysts Set New Price Targets

A number of research analysts have commented on KVUE shares. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and decreased their price objective for the company from $25.00 to $24.00 in a report on Thursday, December 12th. UBS Group lowered their price target on shares of Kenvue from $24.00 to $23.00 and set a “neutral” rating on the stock in a research report on Thursday, January 16th. Barclays cut their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $24.00 target price on shares of Kenvue in a report on Monday. Finally, Bank of America increased their price target on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $23.08.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.